NADH oxidase functions as an adhesin in Streptococcus pneumoniae and elicits a protective immune response in mice

PLoS One. 2013;8(4):e61128. doi: 10.1371/journal.pone.0061128. Epub 2013 Apr 8.

Abstract

The initial event in disease caused by S. pneumoniae is adhesion of the bacterium to respiratory epithelial cells, mediated by surface expressed molecules including cell-wall proteins. NADH oxidase (NOX), which reduces free oxygen to water in the cytoplasm, was identified in a non-lectin enriched pneumococcal cell-wall fraction. Recombinant NOX (rNOX) was screened with sera obtained longitudinally from children and demonstrated age-dependent immunogenicity. NOX ablation in S. pneumoniae significantly reduced bacterial adhesion to A549 epithelial cells in vitro and their virulence in the intranasal or intraperitoneal challenge models in mice, compared to the parental strain. Supplementation of Δnox WU2 with the nox gene restored its virulence. Saturation of A549 target cells with rNOX or neutralization of cell-wall residing NOX using anti-rNOX antiserum decreased adhesion to A549 cells. rNOX-binding phages inhibited bacterial adhesion. Moreover, peptides derived from the human proteins contactin 4, chondroitin 4 sulfotraferase and laminin5, homologous to the insert peptides in the neutralizing phages, inhibited bacterial adhesion to the A549 cells. Furthermore, rNOX immunization of mice elicited a protective immune response to intranasal or intraperitoneal S. pneumoniae challenge, whereas pneumococcal virulence was neutralized by anti-rNOX antiserum prior to intraperitoneal challenge. Our results suggest that in addition to its enzymatic activity, NOX contributes to S. pneumoniae virulence as a putative adhesin and thus peptides derived from its target molecules may be considered for the treatment of pneumococcal infections. Finally, rNOX elicited a protective immune response in both aerobic and anaerobic environments, which renders NOX a candidate for future pneumococcal vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adhesins, Bacterial / genetics
  • Adhesins, Bacterial / immunology
  • Adhesins, Bacterial / metabolism*
  • Aerobiosis
  • Aging / immunology
  • Anaerobiosis
  • Animals
  • Bacterial Adhesion / drug effects
  • Bacterial Vaccines / genetics
  • Bacterial Vaccines / immunology
  • Bacterial Vaccines / metabolism
  • Cell Line
  • Child, Preschool
  • Female
  • Gene Deletion
  • Gene Expression Regulation, Bacterial / drug effects
  • Humans
  • Immunity*
  • Infant
  • Mice
  • Multienzyme Complexes / deficiency
  • Multienzyme Complexes / genetics
  • Multienzyme Complexes / immunology
  • Multienzyme Complexes / metabolism*
  • NADH, NADPH Oxidoreductases / deficiency
  • NADH, NADPH Oxidoreductases / genetics
  • NADH, NADPH Oxidoreductases / immunology
  • NADH, NADPH Oxidoreductases / metabolism*
  • Peptides / pharmacology
  • Streptococcus pneumoniae / drug effects
  • Streptococcus pneumoniae / enzymology*
  • Streptococcus pneumoniae / genetics
  • Streptococcus pneumoniae / immunology

Substances

  • Adhesins, Bacterial
  • Bacterial Vaccines
  • Multienzyme Complexes
  • Peptides
  • NADH oxidase
  • NADH, NADPH Oxidoreductases

Grants and funding

The work was supported by grants from The Israeli Ministry of Health, 4476, 5540 and 3000003867 to Y.M.N, The BG Negev Biotechnology, Ben Gurion University, 80904101 to Y.M.N., The Center of Emerging Diseases, 2506 to Y.M.N., The Israel Academy of Science, 613/04 to Y.M.N. The above funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was also funded by The Ministry of Commerce and Industry to Protea Vaccine Technologies LTD. Through the employment of Shahar Dotan, Michael Tal and Ronald Ellis, Nasvax Ltd/Protea Vaccine Technologies LTD's role involved conceiving, designing and performing the experiments, analyzing the data and writing the manuscript.